System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ahead of print

PubMed: 42471113 DOI: 10.1016/j.ando.2026.102600

Determinants of Glycemic Control with Automated Insulin Delivery in adults living with type 1 diabetes: A 12-Month Sub-Analysis of the French OB2F Registry.

Ann Endocrinol (Paris)

Authors: Michael Joubert, Jean-Baptiste Julla, Eric Renard, Sandrine Lablanche, Agnès Sola, Emmanuel Cosson, Jean-Paul Donnet, Emmanuel Sonnet, Anne Vambergue, Salah Fendri, Lucien Marchand, Amal Lemoine, Laurence Kessler, Mathieu Giraud, Isabela Banu, Elise Pinto Da Rocha, Camille Vatier, Françoise Plat, Aurélie Carlier, Jean-François Gautier, Jean-Pierre Riveline

Affiliations

  • Department of Endocrinology, University Hospital of Caen, UNICAEN, France.
  • Department of Endocrinology, Lariboisière Hospital, AP-HP, Paris, and Université Paris Cité, France.
  • Department of Endocrinology & Diabetes, Montpellier University Hospital, and Institute of Functional Genomics, University of Montpellier, CNRS, INSERM, France.
  • Grenoble Alpes university, Endocrinology-Diabetology Department, Grenoble Alpes University Hospital, France.
  • Department of Diabetology, Cochin Hospital, AP-HP, Paris, France.
  • AP-HP, Department of Endocrinology-Diabetology-Nutrition, Avicenne Hospital, Université Paris 13, Sorbonne Paris Cité, CRNH-IdF, CSO Ile-de-France Nord, Bobigny, France; Université Sorbonne Paris Nord and Université Paris Cité, INSERM, INRAE, CNAM, Center of Research in Epidemiology and StatisticS (CRESS), Nutritional Epidemiology Research Team (EREN), F-93017 Bobigny, France.
  • Department of Endocrinology, Clinique de Choisy, Le Gosier, France.
  • Department of Endocrinology and Diabetology, University Hospital of Brest, France.
  • Department of Diabetology and Nutrition, University of Lille, France.
  • Department of Diabetology, Endocrinology and Nutrition, University Hospital of Amiens, France.
  • Department of Endocrinology and Diabetes, Saint Joseph Saint Luc Hospital, Lyon, France.
  • Department of Diabetology and Endocrinology, Centre Hospitalier de Vienne, France.
  • Department of Endocrinology, Diabetes and Nutrition, Strasbourg University Hospitals, France.
  • Department of Endocrinology and Diabetology, Bretagne Atlantique Hospital Center, France.
  • Department of Diabetology, Endocrinology and Nutrition, Paris Saint-Joseph Hospital, France.
  • Department of Endocrinology, Diabetology and Nutrition, Orléans University Hospital, France.
  • Endocrine Unit, Reproductive Medicine, Reference Center for Rare Endocrine Diseases of Growth and Development (CRMERC), Endo-ERN, Saint-Antoine Hospital, AP-HP, Sorbonne University, France.
  • Department of Endocrinology and Diabetology, Avignon Hospital Center, France.
  • Department of Diabetology and Endocrinology, Bichat Hospital, AP-HP, France.

Abstract

OBJECTIVE

To identify baseline determinants of achieving international continuous glucose monitoring (CGM) targets after 12 months of automated insulin delivery (AID) in adults with type 1 diabetes.

RESEARCH DESIGN AND METHODS

This predefined sub-analysis of the nationwide French OB2F registry included adults with type 1 diabetes initiating MiniMed 780G or Tandem Control-IQ in 2022. Participants required ≥14 consecutive days of CGM data at baseline and 12 months. The primary outcome was achievement of combined CGM targets at 12 months, defined as TIR >70% and TBR <4%. Baseline predictors were assessed using multivariable logistic regression.

RESULTS

Among 1,058 adults, 43% achieved combined CGM targets at 12 months (52% of MiniMed 780G users and 36% of Tandem Control-IQ users). Better baseline metabolic control, including higher TIR and lower HbA1c, TAR, GMI, and glucose variability, was independently associated with target achievement across both systems. Lower baseline TBR predicted target achievement only in MiniMed 780G users. GRI improved in both systems, from 44.1±19.4 to 30.2±13.6 with MiniMed 780G and from 49.4±20.0 to 36.7±14.9 with Tandem Control-IQ.

CONCLUSIONS

Baseline glycaemic profile is the main determinant of achieving international CGM targets after AID initiation in adults with type 1 diabetes, despite substantial improvement in those with poorer baseline control.

MeSH

Diabetes Mellitus, Registries, Achievement, Insulin, Diabetes Mellitus, Type 1, Glycemic Control